UNSPSC 51161538: Eprozinol

This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H30N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IJ21AK8IVJ, chemically known as 1-piperazinepropanol, 4-(beta-methoxyphenethyl)-alpha-phenyl- but generally known as eprozinol, which bears US NIH Compound Identifier 122553. European Medicines Agency schedules Eprozinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06589MIG.

UNSPSC 51161538 Eprozinol (Commodity) covers pharmaceutical products being procured by state and local health agencies through cooperative purchasing frameworks, specifically generic multi-source pharmaceuticals and over-the-counter products supplied to public health facilities across multiple jurisdictions. The work involves manufacturing and supplying identified pharmaceutical products with precise specification data—National Drug Codes (NDCs), SKUs, UPCs, strength, dosage form, and packaging configurations—through authorized wholesale distribution channels; vendors must maintain current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, hold contractual relationships with at least two of three specified wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC), and offer flexible pricing structures including flat price, net price formats, or WAC-minus models. Issuing bodies include multi-state cooperative purchasing alliances administered by state procurement offices on behalf of participating state and local government facilities, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, serving as the primary recent vehicle for this activity.

MMCAP's January 2026 Request for Proposal for generic multi-source pharmaceuticals and OTC products, closing March 26, 2026, represents the primary recent solicitation under this code, spanning Minnesota and Oregon participating jurisdictions. Evaluation emphasizes price competitiveness (75 percent) alongside administrative compliance, EDI capability, and pricing format adherence; vendors must carry $5,000,000 commercial general liability insurance, $2,000,000 network security and privacy liability, and $2,000,000 professional liability coverage. Products must be available in the marketplace by May 15, 2026, with contracts effective July 1, 2026 for a two-year initial term with optional extensions; MMCAP retains sole discretion to award single, dual, or multiple vendors based on therapeutic considerations and patient safety. All submissions route through ePro procurement system using Google Chrome, with pricing and product data in CSV format emailed to MMCAP_Infuse.RFP@state.mn.us; the Q&A cutoff is February 18, 2026.